Vandetanib bei NSCLC – Subgruppe mit erhöhtem klinischem Nutzen

Article Properties
Cite
Schalhorn, Brigitte. “Vandetanib Bei NSCLC – Subgruppe Mit erhöhtem Klinischem Nutzen”. Im Fokus Onkologie, vol. 17, no. 11, 2014, pp. 25-25, https://doi.org/10.1007/s15015-014-1417-2.
Schalhorn, B. (2014). Vandetanib bei NSCLC – Subgruppe mit erhöhtem klinischem Nutzen. Im Fokus Onkologie, 17(11), 25-25. https://doi.org/10.1007/s15015-014-1417-2
Schalhorn, Brigitte. “Vandetanib Bei NSCLC – Subgruppe Mit erhöhtem Klinischem Nutzen”. Im Fokus Onkologie 17, no. 11 (2014): 25-25. https://doi.org/10.1007/s15015-014-1417-2.
Schalhorn B. Vandetanib bei NSCLC – Subgruppe mit erhöhtem klinischem Nutzen. Im Fokus Onkologie. 2014;17(11):25-.
Refrences
Title Journal Journal Categories Citations Publication Date
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer Annals of Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 14 2014
Refrences Analysis
Refrences used by this article by year
Citations
Title Journal Journal Categories Citations Publication Date
Molecular-genetic landscape of abdominal and retroperitoneal desmoid fibromatosis: a retrospective study

 Journal of Modern Oncology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 1 2023
Recurrent desmoid-type retroperitoneal fibromatosis: clinical observation

 Journal of Modern Oncology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 1 2021
Citations Analysis
Category Category Repetition
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens2
The category Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 2 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Recurrent desmoid-type retroperitoneal fibromatosis: clinical observation and was published in 2021. The most recent citation comes from a 2023 study titled Molecular-genetic landscape of abdominal and retroperitoneal desmoid fibromatosis: a retrospective study. This article reached its peak citation in 2023, with 1 citations. It has been cited in 1 different journals, 100% of which are open access. Among related journals, the Journal of Modern Oncology cited this research the most, with 2 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year